BACKLIGHT
10.5.2022 17:54:12 CEST | Business Wire | Press release
Celtx, a leading media production software developer, today announced the release of Celtx Gem, the latest version of its narrative design tool for video game studios that integrates storytelling into production pipelines. Celtx Gem is powered by an entirely new purpose-built technology stack that offers video game developers the ability to architect expansive node-based narrative structures to keep pace with consumers' demand for more immersive storytelling and engaging experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510005304/en/
“A typical screenplay for a two-hour feature film will have, on average, 1,000 lines of dialogue. By comparison, an immersive world video game may have more than 60,000 lines of dialogue that need to be shared with other departments such as design, cinematics, animation, production, and audio,” said Mark Kennedy, Celtx co-founder, and CEO. “Celtx Gem ensures that all teams and departments can easily collaborate at scale.”
Created in development with key partners in the video game industry, Celtx Gem adds new functionality and enhances existing features to help video game developers better manage narrative design. Product highlights include:
- Scalable platform with user-defined hierarchies keeps narrative structures organized for editing and identification.
- Rapid prototyping tools create a highly presentable interactive story map to visualize narrative structures.
- Screenplay-style editor addresses the prevalence of professional film & TV writers joining the industry by offering a familiar writing environment.
- Automated data modeling ensures that all narrative content can be easily exported and integrated with the game production pipeline.
- Logic connects with narrative design through custom conditions and variables, enabling the export of projects in open file formats commonly used in video game production.
- Collaborative tools bring together teams in a cloud-based studio for greater creativity.
“We believe Celtx and their collaborative tool is a key part of our writing pipeline and has been a strong partner supporting our development needs,” says Zac Litton, CTO for Telltale, a leading narrative game development studio and publisher.
Celtx Gem provides the technical lift to accelerate narrative design with features once reserved for in-house-developed narrative design platforms. Today, video games offer more immersive experiences and greater player agency. Video game developers now have a way to manage the large scope of narrative design and content commensurate with lengthy video game development projects.
“Today, narrative-driven AAA game development delivers immersive storytelling experiences on par with traditional entertainment like film and TV,” says Kennedy. “With Celtx Gem, we’ve paired Celtx’s robust story development and media production tools with narrative design tools in a single solution to increase creative collaboration, and help studios shorten their production pipelines.”
To learn how interactive media creators can streamline production with Celtx Gem’s narrative design tools, visit www.celtx.com/gem .
About Celtx
Celtx, a Backlight business, creates cloud-based software for the early stages of media production designed for collaborating, organizing, and producing media projects like film & TV, commercials, documentaries, games and interactive media, and podcasts. Celtx’s software is used by creatives and companies worldwide to achieve streamlined production workflows from concept to camera. For more information, visit www.celtx.com .
About Backlight
Backlight is a media technology company that dramatically improves video content ideation, production, post production and distribution. Launched in 2022 with funding from PSG, Backlight acquired media software businesses ftrack, Celtx, iconik, Wildmoka and Zype. Video-forward organizations utilize Backlight to solve their mission-critical business and operational challenges. Visit www.backlight.co for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005304/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom